PPAR (pan-agonist)

Class

Pan-PPAR agonist

Peroxisome proliferator-activated receptors (PPARs) are a family of three nuclear receptors—PPAR-alpha, PPAR-gamma, and PPAR-delta—that act as transcription factors, meaning they bind DNA and switch genes on or off in response to fatty acid–derived signals. Each subtype predominates in different tissues and governs different aspects of metabolism: PPAR-alpha in the liver regulates fatty acid breakdown and lipoprotein handling, PPAR-gamma in fat and muscle governs insulin sensitivity and fat cell differentiation, and PPAR-delta influences fatty acid oxidation broadly, including in skeletal muscle. A pan-agonist activates all three simultaneously rather than favoring one subtype. The rationale is that many metabolic diseases, such as type 2 diabetes, dyslipidemia, and fatty liver disease with fibrosis, involve simultaneous derangements in glucose handling, lipid metabolism, and energy expenditure that no single PPAR subtype fully addresses. By engaging all three pathways together, a pan-agonist aims to improve insulin sensitivity, normalize circulating lipids, and reduce fat accumulation and inflammatory signaling in the liver in a coordinated fashion. This approach is explored particularly in metabolic-associated fatty liver disease and its more advanced, fibrotic form, as well as in diabetes with mixed lipid abnormalities, where combined metabolic correction may offer broader benefit than targeting one receptor alone.